How to Taper Off Citalopram 40 mg
Discontinue citalopram 40 mg by tapering gradually over 10-14 days minimum, reducing the dose rather than abruptly stopping, to minimize withdrawal symptoms.
Tapering Approach
The FDA drug label for citalopram explicitly states that "a gradual reduction in the dose rather than abrupt cessation is recommended whenever possible" 1. The most relevant guideline evidence indicates that discontinuing an antidepressant over 10 to 14 days limits withdrawal symptoms 2.
Recommended Tapering Schedule
For citalopram 40 mg, a practical approach would be:
- Week 1-2: Reduce to 30 mg daily
- Week 3-4: Reduce to 20 mg daily
- Week 5-6: Reduce to 10 mg daily
- Week 7+: Discontinue completely
This schedule provides gradual dose reductions over approximately 6-7 weeks, well beyond the minimum 10-14 day recommendation, which should minimize withdrawal risk.
Monitoring for Discontinuation Syndrome
Citalopram is associated with discontinuation syndrome, though less prominently than paroxetine, fluvoxamine, or sertraline 3. Watch for these symptoms:
- Dizziness, fatigue, lethargy
- Headaches, myalgias, chills
- Nausea, vomiting, diarrhea
- Insomnia, imbalance, vertigo
- Sensory disturbances, paresthesias
- Anxiety, irritability, agitation
If intolerable symptoms occur following a dose decrease, resume the previously prescribed dose and then decrease more gradually 1.
Important Caveats
Slower Tapering May Be Needed
Recent research suggests that standard 2-4 week tapers may be insufficient for many patients 4. Some evidence indicates that hyperbolic tapering over months, reaching doses much lower than therapeutic minimums, may better prevent withdrawal symptoms 4. However, this conflicts with the established guideline recommendation of 10-14 days 2.
Avoid Alternate-Day Dosing
Do not attempt to taper by switching to every-other-day dosing 5. Recent modeling shows this approach causes pronounced receptor occupancy variation and likely increases withdrawal risk, particularly at lower doses.
Special Populations
For patients over 60 years old, those with hepatic impairment, or CYP2C19 poor metabolizers, the maximum dose should already be limited to 20 mg/day 1. If you're tapering from 40 mg in these populations, the patient may have been on an inappropriately high dose.
Clinical Monitoring
- Monitor patients closely during the first few weeks of tapering for emergence of withdrawal symptoms
- Assess for return of depressive symptoms versus withdrawal syndrome
- Consider using standardized symptom rating scales to track response
- Schedule follow-up within 1-2 weeks of each dose reduction
The key principle is gradual dose reduction with close monitoring, adjusting the taper speed based on individual tolerance rather than rushing discontinuation.